Ignore the Coronavirus Vaccine Sell-Off, Netflix Is Still a Huge Buy
Last week, Pfizer and BioNTech announced their COVID-19 vaccine candidate had a greater than 90% efficacy rate in trials, which climbed to 95% after the companies concluded the Phase 3 study. And this week, Moderna announced its vaccine candidate had a 94.5% efficacy rate in trials, and none of those who received the vaccine caught a severe case of COVID-19.
Obviously, this is unequivocally great news for the U.S. and the world. At the same time, some companies that have seen a tailwind from COVID-19 and the "work from home" environment saw their stock prices get crushed as a result of this positive vaccine news.
Netflix (NASDAQ: NFLX), which has benefited from such a tailwind, saw its shares tank 9% last Monday. But Netflix shareholders should have nothing to fear from a successful vaccine.
Source Fool.com
